Biora Therapeutics Inc Asset Turnover Ratio (BIOR), as of second quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket
 


Biora Therapeutics Inc   (NASDAQ: BIOR)
 

Biora Therapeutics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Biora Therapeutics Inc asset turnover ratio, the ability of Biora Therapeutics Inc 's assets to generate revenue in the second quarter 2026, increased sequentially to 0.11 in the second quarter (Jun 30 2026), BIOR's balance sheet remain strong.

Within sector Biora Therapeutics Inc achieved the highest asset turnover ratio. While asset turnover ranking remained unchanged in the Second Quarter 2026 compared to previous quarter at no. .

Asset Turnover Ratio Definition



BIOR Asset Turnover Ratio (Jun 30 2026)
II. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
(Dec 31 2023)
IV. Quarter
Y / Y Asset Change 231.28 % -56.77 % -64.43 % -55.56 % -42.66 %
Y / Y Revenue Change - - 15800 % 27000 % -
Asset Turnover Ratio (TTM) 0.11 0.04 0.03 0.02 -
BIOR's Total Ranking # # # # #
Seq. Asset Change 592.01 % -17.31 % -23.7 % -24.12 % -9.7 %
Seq. Revenue Change 9946.85 % -89.94 % -41.33 % - -



Asset Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #

Asset Turnover Ratio Statistics
High Average Low
0 0 0
 







Companies with similar Asset Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Assets at quarter ending Jun 30 2026
Tonix Pharmaceuticals Holding Corp   0.11 $ 29.102  Millions$ 260.403  Millions
Beam Therapeutics Inc   0.11 $ 156.035  Millions$ 1,414.853  Millions
Surrozen Inc   0.11 $ 11.511  Millions$ 107.272  Millions
C4 Therapeutics Inc   0.11 $ 35.039  Millions$ 328.207  Millions
Scilex Holding Company  0.11 $ 31.608  Millions$ 297.014  Millions
Ginkgo Bioworks Holdings Inc   0.10 $ 111.863  Millions$ 1,082.996  Millions
Zymeworks Inc   0.09 $ 37.127  Millions$ 404.744  Millions
Nektar Therapeutics  0.09 $ 54.589  Millions$ 610.038  Millions
Bolt Biotherapeutics Inc   0.09 $ 4.700  Millions$ 52.543  Millions
Therapeuticsmd Inc   0.09 $ 3.270  Millions$ 37.859  Millions
Lenz Therapeutics Inc   0.08 $ 21.475  Millions$ 256.428  Millions
Ocular Therapeutix Inc   0.08 $ 52.054  Millions$ 655.696  Millions
Agios Pharmaceuticals Inc   0.08 $ 98.338  Millions$ 1,244.086  Millions
Lipocine Inc   0.08 $ 1.569  Millions$ 20.568  Millions
Longeveron Inc   0.08 $ 1.187  Millions$ 15.629  Millions
Armata Pharmaceuticals Inc   0.07 $ 6.034  Millions$ 81.537  Millions
Intellia Therapeutics Inc   0.07 $ 59.506  Millions$ 845.836  Millions
Cytomx Therapeutics Inc   0.07 $ 18.302  Millions$ 262.601  Millions
Stoke Therapeutics Inc   0.07 $ 27.588  Millions$ 403.985  Millions
Kymera Therapeutics Inc   0.07 $ 105.000  Millions$ 1,539.829  Millions
Catheter Precision Inc   0.07 $ 1.915  Millions$ 28.322  Millions
Ocugen Inc   0.06 $ 4.580  Millions$ 70.556  Millions
Metagenomi Therapeutics Inc   0.06 $ 13.561  Millions$ 209.924  Millions
Nurix Therapeutics Inc   0.06 $ 36.766  Millions$ 595.569  Millions
EBR Systems, Inc.  0.06 $ 6.446  Millions$ 105.295  Millions
Caribou Biosciences Inc   0.06 $ 10.035  Millions$ 165.531  Millions
Grail Inc   0.06 $ 165.263  Millions$ 2,792.551  Millions
Ispecimen inc   0.06 $ 0.466  Millions$ 8.133  Millions
Nexalin Technology Inc   0.05 $ 0.217  Millions$ 4.115  Millions
Prophase Labs Inc   0.05 $ 3.150  Millions$ 60.428  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.